Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | UCHL1 | P09936 | 3/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | CKS1B | P61024 | 2/20 | 0.38 |
| ▸ | SKP1 | P63208 | 2/20 | 0.38 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.38 |
| ▸ | TGM2 | P21980 | 1/20 | 0.38 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13898314 | 0.88 | MAPT (0.51) | ALDH1A1MAPTESR2UCHL1CKS1B | |
| SCHEMBL3903362 | 0.87 | GPR119 (0.40) | UCHL1GRM5TGM2MC4RGPR119 | |
| SCHEMBL1131590 | 0.87 | GPR119 (0.40) | UCHL1GRM5TGM2MC4RGPR119 | |
| SCHEMBL1131364 | 0.81 | SRC (0.42) | ALDH1A1MAPTESR2UCHL1HSD11B1 | |
| SCHEMBL13841896 | 0.80 | GRM5 (0.46) | UCHL1GRM5TGM2MC4RGPR119 | |
| SCHEMBL2840732 | 0.80 | GRM5 (0.46) | UCHL1GRM5TGM2MC4RGPR119 | |
| SCHEMBL10255074 | 0.78 | ALDH1A1 (0.41) | ALDH1A1MAPTESR2UCHL1HSD11B1 | |
| SCHEMBL1131373 | 0.78 | ALDH1A1 (0.41) | ALDH1A1MAPTESR2UCHL1HSD11B1 | |
| SCHEMBL1130847 | 0.77 | HDAC2 (0.49) | GRM5HSD11B1 | |
| SCHEMBL13088807 | 0.75 | UCHL1 (0.56) | UCHL1GRM5HSD11B1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155729-B1 | PROLINAMIDE-TETRAZOLE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-02-16 | — | — | EP | disclosed |
| EP-2155729-A1 | PROLINAMIDE-TETRAZOLE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-02-24 | — | — | EP | disclosed |
| US-7501422-B2 | Prolinamide-tetrazole derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20080306089-A1 | PROLINAMIDE-TETRAZOLE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMAN-LA ROCHE AG (CH) | 2008-12-11 | — | — | US | disclosed |
| WO-2008148688-A1 | PROLINAMIDE-TETRAZOLE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306089-A1 | PROLINAMIDE-TETRAZOLE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | SLC6A3, TAC3, NPSR1 | ALDH1A1 545/4885MAPT 467/4885ESR2 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.